Cheap deal? They paid $50M US up front, don't get 1 share of the...

Cheap deal? They paid $50M US up front, don't get 1 share of the company in return... that is roughly 1/4 of VLA's current market cap for a virus that has never been used in a human, compared to all the trial results VLA has to show!!!!!
Now add the expense of the phase I II program as well as the effort and time.
If anything is "cheap" right now it is VLA's current market cap of just over $200M US, and we only have the BOD to blame for this.
Phase II results like the ones VLA has in the hottest sector in Pharma, immune-oncolgy, and the best the management and BOD can do is a $200M US market cap! Ridiculous.
My only concern with this company is not the science, but that the management and BOD screw it up.